Cohen Klingenstein 13F: New $404K Stake in Moderna (MRNA)

Cohen Klingenstein stepped into biotechnology firm Moderna, Inc. (NasdaqGS: MRNA) by opening a fresh stake, according to a Form 13F filing with the SEC on October 15, 2026. Institutional filings like this one look backward at the previous quarter's activity and may not show where the fund stands today.

What Changed in Cohen Klingenstein's Moderna Position

The fund opened a new position by purchasing 2,100 shares of Moderna. The newly established stake carried a reported market value of $404,397 at the time of the filing.

Other Institutional Activity in Moderna

Other major money managers also adjusted their positions in Moderna around the same period. FMR, LLC grew its holdings by 6,188,477 shares, ending with 51,859,891 shares worth about $11,305,974,552. Blackrock Inc. added 963,178 shares, lifting its total to 30,599,409 shares valued at roughly $6,670,976,988. Vanguard Capital Management LLC boosted its stake by 336,227 shares to own 23,208,792 shares worth about $5,059,748,616. Capital World Investors increased its holdings by 3,578,829 shares, reaching 22,276,996 shares valued at approximately $4,856,607,775. On the other side, BAILLIE GIFFORD & CO trimmed its position by 1,778,708 shares, leaving it with 18,206,778 shares worth about $3,969,259,571.

Moderna, Inc. Stock Down 6.2%

Moderna shares recently traded around $212.26 as of October 16, 2026. That price puts the stock up about 43.4% above its 50-day moving average and roughly 181.4% above its 200-day moving average. The stock trades about 12.4% below its 52-week high of $242.29 and sits well above its 52-week low of $22.28.

Recent Earnings

Moderna reported trailing twelve-month revenue of $2,228,000,000 alongside a negative basic earnings per share of $7.98. The company registered a net margin of -141.4% and a return on equity of -39.0%, with year-over-year revenue growth coming in at 2.1%. The company's next earnings report is scheduled for November 6, 2026.

Insider Buying and Selling at Moderna, Inc.

Company insiders were active in the market prior to the filing. Chief Executive Officer Stephane J Bancel disposed of 499,246 shares valued at $28,715,011 in a transaction dated August 5, 2026. On September 1, 2026, officer Shannon Thyme Klinger sold 3,471 shares at an average price of $139.95 for a total value of $485,766. Chief Financial Officer James M Mock sold 34,836 shares on September 10, 2026, at an average price of $134.49, totaling $4,685,094. Later, on September 15, 2026, President Stephen Hoge disposed of 80,575 shares valued at $11,691,420.

Analysts Set New Price Targets

Wall Street analysts have kept a mixed view on the stock's direction. On August 28, 2026, Argus Research upgraded the stock to a Buy rating with a target of $180.00. Rothschild & Co downgraded the stock to a Sell rating and raised its target from $40.00 to $81.00 on September 3, 2026. Citigroup also downgraded the stock to a Sell rating, raising its target from $60.00 to $80.00 on September 30, 2026. Morgan Stanley maintained an Equal-Weight rating while lifting its target from $89.00 to $95.00 on October 7, 2026. Goldman Sachs maintained a Neutral rating with a target of $137.00 on October 15, 2026. Across the wider analyst community, the stock holds a consensus hold rating with a mean price target of $123.61 based on 18 analyst opinions.

About Moderna

Moderna, Inc. is a Cambridge, Massachusetts-based biotechnology company focused on creating messenger RNA medicines for health needs in the United States and international markets. The company develops vaccines and therapeutics, drawing significant market attention as its clinical pipeline and commercial portfolio evolve.

Bottom Line

Cohen Klingenstein's newly disclosed purchase adds to the ongoing institutional shuffling in Moderna shares. Investors will look toward the company's upcoming earnings release on November 6, 2026, for fresh details on its financial progress and product pipeline. Remember that 13F reports only show positions at the end of the prior quarter and may not reflect current holdings.